CORLINE BIOMEDICAL AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.95 SEK | +6.31% |
|
+0.92% | -26.51% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 288.7 | 250.1 | 249.3 | 313.8 | 198.1 | 320.2 | 221.4 | - |
| Enterprise Value (EV) 1 | 261 | 227.3 | 249.3 | 272.1 | 171.9 | 320.2 | 201.4 | 103.4 |
| P/E ratio | -40.7 x | -25.4 x | -34 x | -42.9 x | 83.8 x | -186 x | -35.5 x | 2.11 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 185 x | 235 x | - | 44.4 x | 8.41 x | - | 6.15 x | 1.24 x |
| EV / Revenue | 167 x | 214 x | - | 38.5 x | 7.3 x | - | 5.59 x | 0.58 x |
| EV / EBITDA | -38.4 x | -23.8 x | - | -39.6 x | 72.1 x | - | -33.6 x | 0.78 x |
| EV / FCF | -51.8 x | -12.2 x | - | -18.8 x | -11.2 x | - | -11.8 x | 1.05 x |
| FCF Yield | -1.93% | -8.22% | - | -5.31% | -8.9% | - | -8.44% | 94.8% |
| Price to Book | 5.25 x | 4.22 x | - | 3.24 x | 2.09 x | - | 2.07 x | 1.04 x |
| Nbr of stocks (in thousands) | 15,775 | 16,675 | 16,675 | 21,491 | 21,491 | 21,491 | 21,491 | - |
| Reference price 2 | 18.30 | 15.00 | 14.95 | 14.60 | 9.220 | 14.90 | 10.30 | 10.30 |
| Announcement Date | 19-02-21 | 20-02-25 | 21-02-26 | 22-02-23 | 23-02-24 | 24-02-14 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.563 | 1.064 | - | 7.062 | 23.55 | - | 36 | 179 |
| EBITDA 1 | -6.792 | -9.531 | - | -6.878 | 2.385 | - | -6 | 133 |
| EBIT 1 | -6.792 | -9.54 | - | -6.909 | 2.329 | - | -6 | 133 |
| Operating Margin | -434.55% | -896.62% | - | -97.83% | 9.89% | - | -16.67% | 74.3% |
| Earnings before Tax (EBT) 1 | -6.793 | -9.54 | - | -6.922 | 2.329 | - | -6 | 133 |
| Net income 1 | -6.793 | -9.54 | -7.287 | -6.922 | 2.329 | -1.809 | -6 | 105 |
| Net margin | -434.61% | -896.62% | - | -98.02% | 9.89% | - | -16.67% | 58.66% |
| EPS 2 | -0.4500 | -0.5900 | -0.4400 | -0.3400 | 0.1100 | -0.0800 | -0.2900 | 4.890 |
| Free Cash Flow 1 | -5.041 | -18.68 | - | -14.45 | -15.3 | - | -17 | 98 |
| FCF margin | -322.52% | -1,755.92% | - | -204.64% | -64.96% | - | -47.22% | 54.75% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 73.68% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 93.33% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 19-02-21 | 20-02-25 | 21-02-26 | 22-02-23 | 23-02-24 | 24-02-14 | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 27.6 | 22.9 | - | 41.6 | 26.2 | - | 20 | 118 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.04 | -18.7 | - | -14.5 | -15.3 | - | -17 | 98 |
| ROE (net income / shareholders' equity) | -13.5% | -16.7% | - | - | - | - | - | 65.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 3.480 | 3.560 | - | 4.510 | 4.400 | - | 4.980 | 9.880 |
| Cash Flow per Share | -0.2700 | -0.8500 | - | -0.2400 | - | - | - | - |
| Capex | 0.94 | 4.84 | - | 9.62 | - | - | - | - |
| Capex / Sales | 59.95% | 455.26% | - | 136.18% | - | - | - | - |
| Announcement Date | 19-02-21 | 20-02-25 | 21-02-26 | 22-02-23 | 23-02-24 | 24-02-14 | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.51% | 20.19M | |
| +4.09% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- CLBIO Stock
- Financials Corline Biomedical AB
